Halozyme Reports Q1 Revenue Up 42% to $377M, Launches $1B Buyback
Halozyme's Q1 revenue rose 42% to $377M with royalty revenue up 43% to $241M, and the company launched a $1B share repurchase program to buy back $400M in 2026. It reaffirmed 2026 guidance: total revenue of $1.71–1.81B, royalty revenue of $1.13–1.17B, adjusted EBITDA of $1.125–1.205B and non-GAAP EPS of $7.75–8.25.
1. Q1 Financial Results
Halozyme reported total revenue of $377 million for the quarter, a 42% increase year-over-year, driven by a 43% rise in royalty revenue to $241 million.
2. Share Repurchase Program
The company launched a new $1 billion share repurchase program, planning to buy back $400 million of common stock in 2026, reflecting confidence in its cash generation and long-term value.
3. 2026 Financial Guidance Reaffirmed
Halozyme reiterated full-year 2026 outlook: total revenues of $1.71–1.81 billion, royalty revenues of $1.13–1.17 billion, adjusted EBITDA of $1.125–1.205 billion and non-GAAP EPS of $7.75–8.25.
4. Collaborations and Pipeline Progress
Recent agreements with Vertex, Oruka and GSK expand the Hypercon and ENHANZE platforms, while new FDA approvals and Phase 3 milestones—including expanded indications for VYVGART Hytrulo and DARZALEX Faspro—bolster near-term and long-term royalty prospects.